Theme 41 of 43

Nutrition, Drug Prices and Access to Health

Prescription-only medicines cost three times more than over-the-counter ones — and restricted prescription drugs, almost four times.

CMED, the chamber regulating drug prices in Brazil, publishes the price ceiling for every presentation sold in the country: 51,140 records with substance, laboratory, therapeutic class and maximum consumer price at each state-VAT band. It is one of the few cases in which the Brazilian state sets the price of a private consumer good, and therefore an unusual portrait of how regulation, prescription requirements and market structure combine to determine what staying healthy costs. Cross-referenced with SISVAN nutritional surveillance data and the Popular Pharmacy programme, the database allows health access to be read through price, not only through service supply.

The more restricted the drug, the more expensive it is

Classifying the 51,140 price records by their control band — Brazil's system indicating the degree of sales control — the gradient is sharp and monotonic. Unbanded, over-the-counter medicines have a median ceiling price of R$ 36.35. Red-band drugs, which require a prescription, cost R$ 103.76: 2.9 times more. Red-band drugs under special restriction reach R$ 143.24, nearly four times the counter medicine. The black band, reserved for psychotropics and narcotics under the strictest control, sits at R$ 81.88, below the ordinary red band — a sign that price is a function not only of control but also of molecule age and generic availability.

Maximum consumer price by control band, median (CMED/ANVISA)
BandRecordsMedian priceRatio vs. unbanded
Unbanded (over the counter)3,644R$ 36.351.0x
Black band1,426R$ 81.882.3x
Red band26,296R$ 103.762.9x
Red band under restriction10,450R$ 143.243.9x

Needing a prescription nearly triples the median price of a medicine — and special restriction nearly quadruples it.

Half the regulated market is ordinary red band

The distribution of records shows where the volume sits: 26,296 red-band presentations represent 51.4% of everything CMED regulates, against just 3,644 (7.1%) over the counter. Brazil's formal pharmaceutical market is therefore overwhelmingly a prescription market — meaning access depends not only on income but on a prior medical appointment, and therefore on the public system's or insurer's capacity to schedule one. Price is the second barrier; the prescription is the first.

Composition of the regulated market by band
BandRecords% of total
Red band26,29651.4%
Red band under restriction10,45020.4%
Unclassified9,32418.2%
Unbanded3,6447.1%
Black band1,4262.8%

Seven of every ten regulated presentations require a prescription — in Brazil, access to medicine runs first through access to a doctor.

Black-band drugs are cheaper than red — and that says something about patents

The counterintuitive finding is that the black band, the strictest control level, has a lower median price (R$ 81.88) than the ordinary red band (R$ 103.76). Tighter sanitary control does not translate into higher price because the two variables measure different things: the band measures abuse and dependency risk, while price reflects patent life, development cost and generic competition. Many black-band psychotropics are old molecules with expired patents and multiple generics available; the red band, by contrast, concentrates recent launches still under exclusivity.

Median price and level of sanitary control
Control levelBandMedian price
Maximum (psychotropics)BlackR$ 81.88
High (special restriction)Restricted redR$ 143.24
Medium (prescription)RedR$ 103.76
NoneUnbandedR$ 36.35

Brazil's most tightly controlled medicine costs less than an ordinary prescription drug — price follows the patent, not the sanitary risk.

Farmácia Popular: four in ten municipalities in the North have no participating pharmacy

Price is one barrier; distance is another. The Farmácia Popular programme, which hands out free medicines for hypertension, diabetes and asthma through participating private pharmacies, had 30,667 active establishments in the Ministry of Health registry in October 2026 — 15.1 per 100,000 inhabitants. The network follows the map of pharmacy retail, not of need: the South has 28.4 participating pharmacies per 100,000 inhabitants, nearly three times the Northeast (9.9). And 1,557 of Brazil's 5,570 municipalities (28%) have none. In the North that is 42.7% of municipalities; in the Northeast, 37.3%.

Pharmacies participating in Farmácia Popular by region (Ministry of Health, registry updated through October 2026; population from the 2022 Census, IBGE)
RegionActive pharmaciesPer 100,000 inhabitantsMunicipalities with none
South8,51328.427.4%
Center-West2,86217.621.8%
Southeast11,86414.016.1%
North2,00411.542.7%
Northeast5,4249.937.3%
Brazil30,66715.128.0%

The programme that gives medicine away for free depends on a participating private pharmacy being in town — and 1,557 Brazilian municipalities have none.

Powerful cross-references

Explanatory hypotheses

The price gradient by band probably measures not the cost of producing the medicine but the competitive structure of each segment: over-the-counter products compete on supermarket and pharmacy shelves, with elastic demand and substitutable brands, while prescription products compete for the doctor's pen, with inelastic demand and substitution limited by the prescription itself. That explains why the black band, dominated by old generic molecules, escapes the pattern. The practical result is that Brazil's regulatory design — tying access to prescription — simultaneously creates real sanitary protection and a cumulative economic barrier: appointment, travel and higher price.

Public policy implications

Expanding the list of prescription-exempt medicines to old molecules with well-established safety profiles would reduce the double barrier of appointment plus price, without meaningful sanitary loss. Broadening generic coverage in red-band classes, where most of the market and the largest price premium sit, would have direct distributive effect. Where there is no participating pharmacy, extending Farmácia Popular's free distribution to primary care units would close the gap in 1,557 municipalities. And routinely publishing median price by therapeutic class, rather than only the ceiling per presentation, would allow monitoring of whether CMED price regulation actually contains cost or merely ratifies prevailing prices.